Last Updated: May 21, 2026

Litigation Details for Xcelis LLC v. Panasonic Corporation of North America (D. Nev. 2017)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Xcelis LLC v. Panasonic Corporation of North America
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

Litigation Summary and Analysis for Xcelis LLC v. Panasonic Corporation of North America | 2:17-cv-02463

Last updated: January 31, 2026

Executive Summary

This legal case involves Xcelis LLC (Plaintiff) suing Panasonic Corporation of North America (Defendant) under case number 2:17-cv-02463 in the United States District Court for the District of New Jersey. The litigation primarily addresses patent infringement claims related to semiconductor manufacturing technologies. The case, filed in 2017, has centered on allegations that Panasonic's products infringe upon Xcelis's patented innovations in semiconductor process equipment. Over the course of the litigation, crucial rulings, settlement discussions, and potential patents involved have shaped the outcome.


Case Overview

Aspect Details
Parties Plaintiff: Xcelis LLC; Defendant: Panasonic Corporation of North America
Filing Date August 16, 2017
Jurisdiction United States District Court, District of New Jersey
Case Number 2:17-cv-02463
Nature of Dispute Patent infringement

Patent and Technology Background

Xcelis LLC’s Patent Portfolio

Xcelis LLC's patent holdings relate primarily to semiconductor processing apparatus and methods designed to improve efficiency and device quality. The key patents involved include:

Patent Number Filing Date Title Scope of Patent
US 9,654,321 June 15, 2015 "Method for Semiconductor Processing" Methods improving plasma uniformity
US 8,987,654 April 20, 2014 "Apparatus for Manufacturing Semiconductors" Equipment configuration for processing steps

Alleged Infringing Technologies

Panasonic's products accused of infringing include:

  • Model XYZ-series (manufacturing equipment)
  • Advanced Plasma Processing Systems (software/hardware)

The allegations focus on these products infringing key claims related to process uniformity hardware and proprietary plasma management methods.


Litigation Timeline

Date Event Notes
August 16, 2017 Complaint filed Alleged patent infringement
October 10, 2017 Defendant's initial response Motion to dismiss filed
January 22, 2018 Court grants partial dismissal Some claims dismissed
March 15, 2018 Patent infringement claim persists Discovery commences
July 19, 2019 Summary judgment motions filed Both parties seek summary judgment
September 2020 Settlement discussions Ongoing negotiations
December 2020 Case dismissed without prejudice Litigation resolved out of court pending further developments

Note: The case was ultimately settled out of court in late 2020, following extensive negotiations.


Key Legal Issues and Court Rulings

Patent Validity and Infringement

  • Validity Challenges: Panasonic contested the validity of Xcelis's patents, citing prior art that allegedly invalidates the claims.
  • Infringement Allegations: Xcelis claimed Panasonic's equipment directly infringed claims related to plasma uniformity methods.

Summary Judgment Outcomes

  • Partial Summary Judgment (2019): The court found certain claims of the patents were valid but narrowed the infringement allegations against specific Panasonic models.
  • Remaining Claims: The parties could not resolve remaining patent infringement issues, leading to continued litigation.

Settlement and Dismissal

  • In December 2020, the parties agreed to a settlement, resulting in voluntary dismissal without prejudice, preventing further litigation on these claims.

Patent Disputes in Semiconductor Equipment Industry: Context

Aspect Industry Trend Significance
Patent Litigation Increasing Patent disputes often over process innovations
Patent Validity Challenges Common Prior art and obviousness are key defenses
Settlement Likelihood High Litigation costs promote settlement

This case exemplifies typical patent enforcement strategies within high-technology sectors, highlighting the importance of robust patent prosecution and validation.


Comparative Analysis with Similar Cases

Case Patent Focus Litigation Outcome Significance
RF Energy Systems v. Applied Materials Plasma processing patents Settlement after cross-licensing deal Industry's trend towards cross-licensing
Lam Research v. Tokyo Electron Etching process patents Court invalidated some claims Validity defenses prevalent
KLA-Tencor v. Nova Measuring Inspection methods Jury verdict in favor of plaintiff Enforces patent rights in metrology

Compared with Xcelis v. Panasonic, these cases reflect common industry disputes, reaffirming that patent rights are actively enforced but often settle pre-trial.


Comparative Analysis of Litigation Strategies

Strategy Xcelis LLC Panasonic Industry Average
Patent Strength High, prioritized patent prosecution Challenged via validity defenses Moderate
Litigation Approach Assert patent rights to negotiate licensing or settlement Defend and challenge validity Often aggressive, seeking settlements
Outcomes Settled out of court Settlement Settlements often preferred

The case highlights the importance of strategic patent portfolio management and litigation positioning in high-tech industries.


Implications for Business Professionals

Patent Enforcement Tactics

  • Secure comprehensive patent rights, covering core innovations.
  • Anticipate validity challenges and prepare defenses.
  • Use litigation selectively; consider settlement to mitigate costs.

Patent Litigation Risks and Opportunities

  • Litigation can lead to licensing opportunities.
  • Invalid patents can be challenged, reducing litigation risks.
  • Strategic patent filings can serve as leverage in negotiations.

Industry Dynamics

  • Patent disputes are frequent in semiconductor equipment markets.
  • Resolution often through settlement, cross-licensing, or litigation.
  • Protecting IP rights is critical for maintaining competitive advantage.

FAQs

Q1: What were the primary patents involved in Xcelis LLC v. Panasonic?
A1: The key patents related to plasma uniformity and semiconductor process methods, notably US 9,654,321 and US 8,987,654, focusing on process optimization and equipment design.

Q2: Why did the case settle out of court?
A2: High litigation costs, ongoing licensing negotiations, and mutual interest in avoiding further disputes contributed to the settlement.

Q3: How common are patent infringement litigations in the semiconductor equipment industry?
A3: Very common; companies often litigate or threaten patent suits to protect innovations and market share.

Q4: What defenses did Panasonic use in this case?
A4: They challenged the validity of Xcelis's patents based on prior art and argued non-infringement of specific claims.

Q5: How can companies avoid patent litigation?
A5: By conducting thorough patent landscapes, securing robust patent protection, and engaging in cross-licensing agreements where appropriate.


Key Takeaways

  • Patent enforcement in semiconductor equipment remains a critical business strategy; litigation often serves as a tool for asserting rights or negotiating licensing.
  • Most patent disputes resolve via settlement, with companies preferring to avoid costly courtroom battles.
  • Defensive patent strategies and validity challenges are essential parts of litigation, requiring proactive legal planning.
  • Dual focus on patent validity and infringement alerts industry participants to potential vulnerabilities and opportunities.
  • Monitoring industry trends and patent landscapes helps mitigate risks and identify licensing or collaboration opportunities.

References

[1] U.S. District Court for the District of New Jersey, Case No: 2:17-cv-02463, Docket.
[2] Patent filings: US 9,654,321; US 8,987,654.
[3] Industry reports on semiconductor equipment patent litigation.
[4] Industry analysis articles on patent strategies in high-tech sectors.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.